Summary

A.S. Watson, the health and beauty group that owns Superdrug and The Perfume Shop and sits within Li Ka-shing's CK Hutchison, has been widely reported through 2026 to be weighing a large stock market flotation, possibly split between London and Hong Kong. Reports have cited a group valuation around 30bn US dollars and a raise of roughly 2bn, with advisers said to include Goldman Sachs and UBS, but the company has confirmed none of this. More recent coverage has raised the prospect of a delay into 2027, citing regulatory and other complications in Asia. Reporting also says the primary venue is still being debated and the plan remains subject to market conditions. London would gain visibility from a rare large consumer listing, but gilt-market pressure, rising mortgage rates and an energy shock from the US-led conflict with Iran all argue for caution. Any delay would most likely reflect timing rather than a verdict on London.

Five Key Takeaways

  1. A large flotation of Superdrug's owner has been widely reported, but the company has not confirmed it, and every key detail, including whether it happens at all, remains uncertain.
  2. The listing has been described as a dual London and Hong Kong deal, with reports saying the primary venue is still being debated rather than settled.
  3. Reported valuations of around 30bn US dollars and a raise of roughly 2bn should be read as press estimates, not official figures.
  4. London would gain prestige and visibility from a rare large consumer listing, but its recent thin pipeline is exactly why market conditions matter so much.
  5. Any delay would most likely reflect timing and Asian regulatory complications rather than a verdict on London itself, and the situation could change quickly.

What Happened

For much of 2026, the City has been talking about a company that has said very little. A.S. Watson, the Hong Kong-based health and beauty group that owns Superdrug and The Perfume Shop in Britain, has been the subject of repeated reports that it is preparing a large stock market flotation. Those reports, not any formal announcement, are the story.

The accounts share a broad outline. A.S. Watson is said to be considering an initial public offering split between two venues, London and Hong Kong, in what has been described as a dual listing. Several reports have attached a headline valuation of around 30bn US dollars to the wider group, and suggested a fundraising of roughly 2bn dollars, or about 1.5bn pounds.

More recently, the tone of the coverage has shifted. Where earlier reports pointed to a listing before the end of 2026, later accounts have raised the possibility of a delay, with some suggesting the float could slip into 2027. Regulatory and other complications in Asia have been cited as reasons, again on a reported rather than confirmed basis.

It is worth being precise about what is known and what is not. The company has not published a prospectus, confirmed a timetable, or named a definitive venue. Reports have said the primary location of any float is still being debated, and that the whole plan remains subject to market conditions. Bankers at Goldman Sachs and UBS, and lawyers at Latham & Watkins, have been named as advisers, though even that reflects press reporting rather than official disclosure.

A.S. Watson sits within CK Hutchison, the sprawling conglomerate built by the Hong Kong billionaire Li Ka-shing. Singapore's state investment company, Temasek, holds a large minority stake, reported at close to a quarter of the retail arm, and a listing would offer one route for such an investor to realise part of its holding. Superdrug itself is a familiar high-street name, and its UK accounts have pointed to revenues of about 1.6bn pounds in 2024, underlining why a flotation of the parent draws British attention.

Why It Matters

The interest is not really about Superdrug's shops, which continue to trade as normal whatever their ultimate owner decides. It is about what a listing of this size would say about London as a place to raise money, at a moment when that question is unusually live.

London has endured a lean spell for new listings. Reports covering 2026 have pointed to only a handful of flotations on the London Stock Exchange, raising a modest combined sum for the year. A single large, recognisable consumer business choosing to list in the City, even in part, would stand out against that thin backdrop and would be read as a vote of confidence.

That is why the shift in reporting, from an imminent listing towards a possible delay, carries symbolic weight. The London market has watched several companies choose New York, and others disappear through takeover, in recent years. A high-profile deal that hesitates, or lists elsewhere, feeds an anxious narrative about the City's pulling power, whether or not that reading is fair.

For the new government, the timing is awkwardly relevant. Andy Burnham entered Downing Street on 20 July 2026 promising investment and growth, and ministers have made no secret of wanting London to compete harder for global capital. The health of the listing market is one visible measure against which that ambition will be judged, even though a single company's private decision is well beyond any government's control.

There is a note of caution that runs through all of this. Because the plan is reported rather than confirmed, the significance can easily be overstated. A delay driven by complications in Asia would say little about London specifically, and a decision to weight the listing towards Hong Kong would reflect the company's own centre of gravity as much as any judgement on the City.

Even so, the episode is a useful window onto the calculations that now shape where big companies choose to float, and onto the balance of factors that make London attractive to some issuers and less so to others.

Detailed Analysis

To weigh whether market uncertainty could delay a Superdrug-owner listing, it helps to separate three questions that often get blurred together. What is actually confirmed, what would draw such a company to London, and what could push the timing back or send it elsewhere. Each deserves its own treatment, because the honest answer to the first is: less than the headlines imply.

Separating the confirmed from the speculative

The first discipline is to be clear about the evidence. A.S. Watson has not, on the public record, announced an intention to float, set a price range, or committed to a venue. What exists is a series of press reports, some citing unnamed sources, describing plans that are said to be under consideration.

That matters because the specifics vary between accounts. Valuations in the region of 30bn US dollars have appeared, but other framings and figures have circulated too, and none carries the authority of an official filing. Any number quoted today should be treated as an estimate that could move sharply, or prove wide of the mark, once real terms emerge, if they ever do.

The venue is similarly unsettled. Reports have described a dual listing in London and Hong Kong while also saying the primary location is still being debated. Those two statements sit together uneasily, and the natural reading is that the company is keeping its options open rather than following a fixed plan. A deal weighted towards Hong Kong, with London in a supporting role, would look very different from a London-led flotation.

For readers, the practical takeaway is modest but important. It is reasonable to say that a large listing involving Superdrug's owner has been widely discussed and may be in preparation. It is not reasonable to assume it will happen, happen in London, or happen on any particular date.

What would make London attractive, or not

Set the specific deal aside and ask a more general question: why might a global consumer group choose to list in London, and why might it hesitate? The answer explains a great deal about the current mood in the City.

On the attractive side, London remains a deep, well-regulated market with a long history of hosting large consumer and retail names, a global investor base, and the credibility that comes with a premium listing. For a business with a substantial British high-street presence through Superdrug and The Perfume Shop, a London quotation offers visibility with UK customers, staff and suppliers, and access to sterling investors who understand the domestic market. Regulators have also loosened the listing rulebook in recent years, aiming to make the City simpler and more flexible for issuers.

The reservations are equally well rehearsed. Critics point to persistently lower valuations in London than in New York, thinner trading in some stocks, and a shrinking pool of listed companies that can make the market feel less dynamic. A company that fears its shares will be valued more cautiously in London than elsewhere has a rational reason to look abroad, or to split its listing to capture different investor bases.

For an Asia-centred group, the pull of Hong Kong is its own factor rather than a criticism of London. Hong Kong offers proximity to the company's headquarters, familiarity with its structure and management, and access to Asian capital that knows the brand. A dual listing can be an attempt to have both, tapping European and Asian investors at once, though it also adds cost and complexity.

The balance, then, is genuinely finely poised, and reasonable advisers could reach different conclusions. That ambiguity is precisely why market conditions carry so much weight in the final decision, and why a firm timetable has been so hard to pin down in the reporting.

How market conditions could delay a listing

Even a company fully committed to floating will not do so into an unwelcoming market. Timing an initial public offering is partly an art, and issuers routinely wait for a window in which investor appetite, valuations and volatility all look favourable. That is the ordinary mechanism by which a delay happens, with no drama attached.

The current environment gives issuers plenty to think about. Gilts have been under pressure as investors weigh higher spending under the new government, and UK mortgage rates rose again after a resumption of Middle East hostilities, with several big lenders raising fixed rates. The US-led conflict with Iran has fed an energy-price shock that has rippled through markets. None of this makes a listing impossible, but it raises the risk that a float launched at the wrong moment prices poorly.

There are also company-specific reasons a timetable can slip that have nothing to do with London. Reports on the Superdrug owner have pointed to regulatory and other complications in Asia, the sort of issue that can delay any large cross-border transaction while it is resolved. Structuring a dual listing across two regulatory regimes is intricate, and it is common for such deals to take longer than first briefed.

It is worth stressing what a delay would and would not mean. Pushing a listing from one year to the next is a normal commercial judgement, not evidence that a company has abandoned its plans or turned against a particular venue. Many flotations that eventually proceed are trailed, paused and retimed more than once before they arrive.

The fairest conclusion is that market uncertainty could indeed delay a listing, because that is true of almost any IPO under current conditions. But a delay to this particular deal, if it comes, would most plausibly reflect timing and Asian complications rather than a considered rejection of London, and the picture could look quite different within months as conditions shift.

What Happens Next

The most likely near-term development is more of the same: further reports, refinements and denials, without a definitive statement from the company. Until A.S. Watson chooses to confirm its intentions, the outside world is left reading signals rather than facts.

The clearest evidence, when it comes, will be procedural. A published intention to float, the appointment of a sponsor, a confirmed venue or a price range would each mark a real step and would settle questions that speculation cannot. Investors and journalists will watch for those markers rather than for further unsourced valuations.

Market conditions will remain the swing factor. If gilt yields steady, energy prices calm and equity markets stay firm, a window could open in which a large listing looks attractive. If volatility persists, the incentive to wait grows, and a slip into 2027 would surprise no one.

For London, the wider contest for listings continues regardless of this one deal. The reforms already made to the listing regime, and the government's stated ambition to attract capital, will be judged over years and many transactions. A Superdrug-owner listing would be a welcome headline, but its absence would not by itself prove anything.

The sensible posture for readers is patience matched with scepticism. Treat each new report as one more piece of an incomplete picture, note that the company has confirmed nothing, and expect the story to evolve, possibly for many months, before anything is settled.

Conclusion

The question in the headline, whether market uncertainty could delay a London listing, has an honest but unsatisfying answer: it could, and so could a dozen other factors, but only if there is a listing to delay in the first place.

What is solid is that A.S. Watson, the owner of Superdrug, has been widely reported to be weighing a large flotation, possibly split between London and Hong Kong, and that reports have more recently raised the prospect of a delay. What is not solid is almost everything else, from the exact valuation to the primary venue to the timing.

That uncertainty is the point rather than a gap to be filled. A dual-listing candidate of this scale sits at the intersection of London's ambitions, Hong Kong's gravitational pull, and a jittery market shaped by energy shocks and rising rates. Any of those forces could tip the timetable, and none has yet been resolved in public.

For the City, the episode is a reminder that confidence is built on completed deals, not reported ones, and that a healthy listing market is measured over time. For readers, it is a case study in reading business news carefully: the difference between what has been announced and what has merely been said matters, and here almost all of it belongs firmly in the second category. This article is analysis of a developing story, not financial advice, and the picture may well change.